We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Trachea Tissue-Engineered by Researchers

By Biotechdaily staff writers
Posted on 28 Oct 2005
In a new study, researchers have used tissue engineering to reconstruct defective tracheas in fetal lambs, using cells from the amniotic fluid to grow sections of the cartilage tube and then implanting those living grafts into the lambs while still in the womb.

Amniotic fluid is easy to collect during pregnancy and contains mesenchymal stem cells that can make many of the tissues needed for repairs, according to Dario Fauza, M.D., a pediatric surgeon who led the study. More...
The study results, from the Children's Hospital Boston (MA, USA), were reported at the annual meeting of the American Academy of Pediatrics in Washington (DC, USA) in October 2005.

Tracheal defects are rare but life-threatening. Surgeons have tried various ways to fix defects but have had limited success. Dr. Fauza's team multiplied the amniotic mesenchymal cells in culture, then "seeded” them onto biodegradable tubes of the required dimensions and shape. After exposure to growth factors, the cells differentiated into cartilage cells. When these grafts were ready, they were used to reconstruct defective tracheas in seven fetal lambs. When the lambs were born, all five that survived to term were able to breathe spontaneously at birth.

Although many congenital defects can be safely repaired after birth, Dr. Fauza's goal is to fix tracheal defects in utero, eliminating the complications of intubation and ventilation. "The fetus doesn't need the trachea, so the repair would have time to heal in utero,” he explained. "And fetal healing is very good--it's better than adult healing.”

Since the grafts are made from the baby's own cells, there is no risk of the immune system rejecting the tissues. Furthermore, amniotic fluid is readily available. Less than two tablespoons provide enough fetal cells to repair a malformation.






Related Links:
Children's Hospital Boston

New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Electrolyte Analyzer
BKE-B
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.